Table: q1_q4_2023_prescription_drugs_intro_to_market , manufacturer_name like Z*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name ndc_number drug_product_description drug_category drug_category_source date_introduced_to_market wac_at_introduction marketing_pricing_plan_description marketing_pricing_plan_non_public_indicator estimated_number_of_patients breakthrough_therapy_indicator priority_review_indicator acquisition_date acquisition_price acquisition_price_non_public_indicator acquisition_price_comment general_comments supporting_documents
Zydus Pharmaceuticals (USA) Inc. 68382076906 Topiramate ER Capsules 100mg 30ct Generic FDA 2023-01-04 822.2600 None 1 42400000 None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “42,400,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Topiramate ER Capsules is indicated for the treatment of epileptic seizures and for the treatment of migraines. As per the CDC link "Frequently asked questions about Epilepsy" (https://www.cdc.gov/epilepsy/about/faq.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fepilepsy%2Fbasics%2Ffaq.htm) about 3.4 million people in the United States have active epilepsy. Also, as per the link "How Common is Migraine?" (https://migraine.com/migraine-statistics) roughly 39 million people in the United States have migraine. For this reason we have put in a number of 42.4 million in estimated number of patients. None
Zydus Pharmaceuticals (USA) Inc. 70710103007 Lenalidomide 2.5mg Capsule (28 CAPS) Generic FDA 2023-03-06 20157.3600 None 1 60000 None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “60,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Lenalidomide is indicated for the treatment of Multiple Myeloma. As per the University of California San Francisco link (https://www.ucsfhealth.org/conditions/multiple-myeloma#) about 60,000 people have this disease and 20,000 new cases are diagnosed each year in the United States. None
Zydus Pharmaceuticals (USA) Inc. 70710103408 Lenalidomide 20mg Capsule (21 CAPS) Generic FDA 2023-03-06 15118.0400 None 1 60000 None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “60,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Lenalidomide is indicated for the treatment of Multiple Myeloma. As per the University of California San Francisco link (https://www.ucsfhealth.org/conditions/multiple-myeloma#) about 60,000 people have this disease and 20,000 new cases are diagnosed each year in the United States. None
Zydus Pharmaceuticals (USA) Inc. 68382035201 Sirolimus 2mg Tablets (100 ct) Generic FDA 2023-03-23 1186.3400 None 1 25000 None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “25,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Sirolimus is indicated to prevent rejction of a kidney transplant. As per Organ Procurement & Transplantation Network (OPTN) link (https://optn.transplant.hrsa.gov/news/2022-organ-transplants-again-set-annual-records-organ-donation-from-deceased-donors-continues-12-year-record-setting-trend/) upwards of 25,000 people in the United States had first time kidney transplants in 2022. For this reason we are estimating approximately 25,000 patients. None
Zydus Pharmaceuticals (USA) Inc. 70710189506 Arsenic Trioxide Injection (NovaPlus N+) 10mg/10ml Generic FDA 2023-04-24 3790.5000 None 1 5000 None None None None None None This is an AP rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “5,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Arsenic Trioxide is indicated for the treatment of acute promyelocytic leukemia (APL). As per NIH GARD (Genetic and Rare Diseases Information Center) link (https://rarediseases.info.nih.gov/diseases/538/acute-promyelocytic-leukemia) fewer than 5,000 people in the United States have this disease. For this reason we are estimating approximately 5,000 patients. None
Zydus Pharmaceuticals (USA) Inc. 70710189606 Arsenic Trioxide Injection (NovaPlus N+) 12mg/6ml Generic FDA 2023-04-24 5388.7700 None 1 5000 None None None None None None This is an AP rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “5,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Arsenic Trioxide is indicated for the treatment of acute promyelocytic leukemia (APL). As per NIH GARD (Genetic and Rare Diseases Information Center) link (https://rarediseases.info.nih.gov/diseases/538/acute-promyelocytic-leukemia) fewer than 5,000 people in the United States have this disease. For this reason we are estimating approximately 5,000 patients. None
Zydus Pharmaceuticals (USA) Inc. 70710120801 Plerixafor Inj. 24mg/1.2mL (1X1.2mL) Generic FDA 2023-07-26 1200.0000 None 1 20000 None None None None None None This is an AP rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “20,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Plerixafor is indicated for the peripheral mobilization of hematopoietic stem cells for those patients with certain types of cancer (non-Hodgkin's lymphoma-NHL, multiple myeloma-MM) to prepare them for stem cell transplant. As per NIH LIbrary of Medicine National Center for Biotechnology Information link regarding the Prevalence of Hemtopoietic Cell Transplant Survivors in the United States (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779514/#) approximately 20,000 patients receive HCT (hematopoietic cell transplantation) each year in the USA. For this reason we are estimating approximately 20,000 patients. None
Zydus Pharmaceuticals (USA) Inc. 70710185207 Indomethacin Suppositories 50mg Generic FDA 2023-08-03 10314.2900 None 1 1300000 None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “1,300,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Indomethacin Suppository is indicated for for moderate to severe ankylosing spondylitis, osteoarthritis, rheumatoid arthritis or gouty arthritis in adults and children older than 14 years of age. As per NIH LIbrary of Medicine National Center for Biotechnology Information link regarding the Prevalence Trend and Disparities in Rheumatoid Arthritis amound US Adults 2005-2018 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348893/#) approximately 1.3 million adults suffer from RA, representing 0.6% to 1% of the adult population. For this reason we are estimating approximately 1.3 million patients. None
Zydus Pharmaceuticals (USA) Inc. 70710192601 Sodium Phenylacetate and Sodium Benzoate 10%-10% Inj. 20ml (1 vial) Generic FDA 2023-09-25 2500.0000 None 1 2396 None None None None None None This is an AP rated generic product that is distributed by Zydus. Acquisition date and price are not applicable. Zydus has entered “2,396” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic distributor is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Sales volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Sodium Phenylacetate and Sodium Benzoate is indicated for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiences in enzymes of the urea cycle. As per NIH LIbrary of Medicine National Center for Biotechnology Information link regarding Hyperammonemia ( https://www.ncbi.nlm.nih.gov/books/NBK557504/#), its prevalence is estimated to be 1:140000. Based on the USA population counter clock dated September 27, 2023, the US population is 335,491,897 which was divided by 140,000 to arrive at the 2,396 patients. None
Zydus Pharmaceuticals (USA) Inc. 68382048116 Pitavastatin Calcium 1mg Tablets Generic FDA 2023-11-02 828.7400 None 1 93000000 None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “93,000,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4).Pitavastatin Calcium is indicated for hyperlipidemia (or high cholesterol). As per the Cleveland Clink link regarding Hyperlipidemia (https://my.clevelandclinic.org/health/diseases/21656-hyperlipidemia) approximately 93 million adults age 20 and older have a total cholesterol count above the recommended limit of 200mg/dL. For this reason we are estimating approximately 93 million patients. None
Zydus Pharmaceuticals (USA) Inc. 68382048216 Pitavastatin Calcium 2mg Tablets Generic FDA 2023-11-02 828.7400 None 1 93000000 None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “93,000,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4).Pitavastatin Calcium is indicated for hyperlipidemia (or high cholesterol). As per the Cleveland Clink link regarding Hyperlipidemia (https://my.clevelandclinic.org/health/diseases/21656-hyperlipidemia) approximately 93 million adults age 20 and older have a total cholesterol count above the recommended limit of 200mg/dL. For this reason we are estimating approximately 93 million patients. None
Zydus Pharmaceuticals (USA) Inc. 68382048316 Pitavastatin Calcium 4mg Tablets Generic FDA 2023-11-02 828.7400 None 1 93000000 None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “93,000,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4).Pitavastatin Calcium is indicated for hyperlipidemia (or high cholesterol). As per the Cleveland Clink link regarding Hyperlipidemia (https://my.clevelandclinic.org/health/diseases/21656-hyperlipidemia) approximately 93 million adults age 20 and older have a total cholesterol count above the recommended limit of 200mg/dL. For this reason we are estimating approximately 93 million patients. None
Zydus Pharmaceuticals (USA) Inc. 70710183805 Methylene Blue 50mg/10mL Solution for injection (5 x 10ml) Generic FDA 2023-12-07 1171.9400 None 1 3000 None None None None None None This is an AP rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “3,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4).Methylene Blue Solution for Injection is indicated for methemoglobinemia. As per the Jama Network link regarding Risk of Topical Anesthetic Induced Methemoglobinemia (https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1673755#) as many as 3,000 cases of methemoglobinemia overall may occur annually in the United States. For this reason we are estimating approximately 3,000 patients. None
Zydus Pharmaceuticals (USA) Inc. 68382035806 Topiramate ER Capsules 200mg 30ct TK Generic FDA 2023-12-12 1125.2400 None 1 42400000 None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “42,400,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Topiramate ER Capsules is indicated for the treatment of epileptic seizures and for the treatment of migraines. As per the CDC link "Frequently asked questions about Epilepsy" (https://www.cdc.gov/epilepsy/about/faq.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fepilepsy%2Fbasics%2Ffaq.htm) about 3.4 million people in the United States have active epilepsy. Also, as per the link "How Common is Migraine?" (https://migraine.com/migraine-statistics) roughly 39 million people in the United States have migraine. For this reason we have put in a number of 42.4 million in estimated number of patients. None